In this study, we discovered that six cancer-specific cellular signaling pathways, the irinotecan pathway, metabolism, androgen receptor signaling, interferon signaling, MAPK/NF-kB signaling, and the tamoxifen pathway, were altered in the ETV4 subtype of prostate cancer. This evidence concerns the gene NFKB1 and prostate cancer.